B- PRISM (Precision Intervention Smoldering Myeloma): A Phase II Trial of Combination of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma
The purpose of this research study is to learn whether the combination of daratumumab SC ( Darzalex Faspro), lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone works in treating smoldering multiple myeloma and preventing progression to active or symptomatic multiple myeloma.
The names of the study drugs involved in this study are:
- Daratumumab (also called Darzalex Faspro)
- Bortezomib (also called Velcade)
- Lenalidomide (also called Revlimid)
- Dexamethasone
Contact
Clinical Trials Office at [email protected] or (203) 358-8879.
Principal Investigator(s)
Kelsey Sokol, MD
Sponsor(s)
Dana-Farber Cancer Institute
Location
Bennett Cancer Center
One Hospital Plaza
Stamford, CT 06902
Main: 203-358-8879
Stamford, CT 06902
Main: 203-358-8879